Cargando…

Reactivation of Tuberculosis in the Setting of COVID-19 Infection

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) was declared a pandemic by WHO in March 2020. The causative organism has since undergone a series of mutations. COVID-19 primarily being a respiratory illness causes pre-existing pulmonary dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Noori, Muhammad Atif Masood, Younes, Islam, Latif, Asnia, Fichadiya, Hardik, Elkattawy, Sherif, Khandait, Harshwardhan, Nawachukwu, Onyeka, Garg, Vipin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033637/
https://www.ncbi.nlm.nih.gov/pubmed/35481299
http://dx.doi.org/10.7759/cureus.23417
_version_ 1784692938475831296
author Noori, Muhammad Atif Masood
Younes, Islam
Latif, Asnia
Fichadiya, Hardik
Elkattawy, Sherif
Khandait, Harshwardhan
Nawachukwu, Onyeka
Garg, Vipin
author_facet Noori, Muhammad Atif Masood
Younes, Islam
Latif, Asnia
Fichadiya, Hardik
Elkattawy, Sherif
Khandait, Harshwardhan
Nawachukwu, Onyeka
Garg, Vipin
author_sort Noori, Muhammad Atif Masood
collection PubMed
description Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) was declared a pandemic by WHO in March 2020. The causative organism has since undergone a series of mutations. COVID-19 primarily being a respiratory illness causes pre-existing pulmonary diseases to show worse clinical outcomes. About one-third of the world’s population is thought to be infected with latent Mycobacterium tuberculosis (MTB). Both previous and newly developed tuberculosis (TB) infection are risk factors for COVID-19 and are associated with poor outcomes. T lymphocytes play a pivotal role in defense against MTB and with evidence suggesting depletion of T lymphocytes in COVID-19, it can be postulated that COVID-19 can increase the risk of reactivation of latent TB.  Given that a large population around the globe is infected with latent tuberculosis, it is interesting to study and note cases where the virus leads to the reactivation of latent tuberculosis infection. Herein, we present a 76-year-old Brazilian male recently treated for COVID-19 pneumonia, presenting with new-onset cough and weakness diagnosed with latent MTB reactivation. 
format Online
Article
Text
id pubmed-9033637
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-90336372022-04-26 Reactivation of Tuberculosis in the Setting of COVID-19 Infection Noori, Muhammad Atif Masood Younes, Islam Latif, Asnia Fichadiya, Hardik Elkattawy, Sherif Khandait, Harshwardhan Nawachukwu, Onyeka Garg, Vipin Cureus Internal Medicine Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) was declared a pandemic by WHO in March 2020. The causative organism has since undergone a series of mutations. COVID-19 primarily being a respiratory illness causes pre-existing pulmonary diseases to show worse clinical outcomes. About one-third of the world’s population is thought to be infected with latent Mycobacterium tuberculosis (MTB). Both previous and newly developed tuberculosis (TB) infection are risk factors for COVID-19 and are associated with poor outcomes. T lymphocytes play a pivotal role in defense against MTB and with evidence suggesting depletion of T lymphocytes in COVID-19, it can be postulated that COVID-19 can increase the risk of reactivation of latent TB.  Given that a large population around the globe is infected with latent tuberculosis, it is interesting to study and note cases where the virus leads to the reactivation of latent tuberculosis infection. Herein, we present a 76-year-old Brazilian male recently treated for COVID-19 pneumonia, presenting with new-onset cough and weakness diagnosed with latent MTB reactivation.  Cureus 2022-03-23 /pmc/articles/PMC9033637/ /pubmed/35481299 http://dx.doi.org/10.7759/cureus.23417 Text en Copyright © 2022, Noori et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Noori, Muhammad Atif Masood
Younes, Islam
Latif, Asnia
Fichadiya, Hardik
Elkattawy, Sherif
Khandait, Harshwardhan
Nawachukwu, Onyeka
Garg, Vipin
Reactivation of Tuberculosis in the Setting of COVID-19 Infection
title Reactivation of Tuberculosis in the Setting of COVID-19 Infection
title_full Reactivation of Tuberculosis in the Setting of COVID-19 Infection
title_fullStr Reactivation of Tuberculosis in the Setting of COVID-19 Infection
title_full_unstemmed Reactivation of Tuberculosis in the Setting of COVID-19 Infection
title_short Reactivation of Tuberculosis in the Setting of COVID-19 Infection
title_sort reactivation of tuberculosis in the setting of covid-19 infection
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033637/
https://www.ncbi.nlm.nih.gov/pubmed/35481299
http://dx.doi.org/10.7759/cureus.23417
work_keys_str_mv AT noorimuhammadatifmasood reactivationoftuberculosisinthesettingofcovid19infection
AT younesislam reactivationoftuberculosisinthesettingofcovid19infection
AT latifasnia reactivationoftuberculosisinthesettingofcovid19infection
AT fichadiyahardik reactivationoftuberculosisinthesettingofcovid19infection
AT elkattawysherif reactivationoftuberculosisinthesettingofcovid19infection
AT khandaitharshwardhan reactivationoftuberculosisinthesettingofcovid19infection
AT nawachukwuonyeka reactivationoftuberculosisinthesettingofcovid19infection
AT gargvipin reactivationoftuberculosisinthesettingofcovid19infection